All the news Showing 10 of 65 articles from: Antiviral therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Hepatitis B patients on long-term entecavir or tenofovir have low mortality, but liver cancer remains a risk Liz Highleyman / 03 June 2015 More than 95% of people with chronic hepatitis B were still alive after five years on antiviral therapy with entecavir (Baraclude) or tenofovir (Viread) and most deaths were due to non-liver-related causes, according ... Stopping tenofovir is safe for people with hepatitis B on long-term therapy Liz Highleyman / 02 June 2015 Most people with hepatitis B virus (HBV) who stopped taking tenofovir (Viread) after more than three years on treatment had good outcomes, according to a presentation at the recent European Association for the ... Nucleic acid polymer REP 2139-Ca shows promising activity against hepatitis B and hepatitis delta Liz Highleyman / 15 May 2015 The nucleic acid-based polymer REP 2139-Ca lowered hepatitis B surface antigen (HBsAg) levels and significantly reduced hepatitis B and hepatitis delta viral loads when combined with immunotherapy, according to presentations at the European ... Expanded vaccination and treatment could help eliminate hepatitis B worldwide Liz Highleyman / 28 April 2015 While universal infant hepatitis B virus (HBV) vaccination has already led to major advances in reducing new infections in some settings, further expansion of prevention and treatment are needed to significantly reduce HBV ... Cancer drug shows promise as cure for hepatitis B Science Daily / 21 April 2015 Arrowhead initiates phase 2b trial for potential HBV drug Healio Hepatology / 14 April 2015 WHO issues its first hepatitis B treatment guidelines World Health Organization / 12 March 2015 Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients Liz Highleyman / 05 February 2015 People with chronic hepatitis B virus (HBV) infection are more likely to experience favourable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir – ... Entecavir and tenofovir work well for people with drug-resistant hepatitis B virus Liz Highleyman / 04 February 2015 A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the European ENTEBE study presented at the American Association for ... FDA places Arrowhead Hepatitis B drug on partial hold, shares plunge Reuters / 13 January 2015 ← Prev1...34567Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive